loading
Karyopharm Therapeutics Inc stock is traded at $3.70, with a volume of 15,074. It is down -1.07% in the last 24 hours and down -53.46% over the past month.
See More
Previous Close:
$3.74
Open:
$3.7
24h Volume:
15,074
Relative Volume:
0.15
Market Cap:
$36.61M
Revenue:
$140.46M
Net Income/Loss:
$-146.34M
P/E Ratio:
-2.9134
EPS:
-1.27
Net Cash Flow:
$-117.73M
1W Performance:
-33.93%
1M Performance:
-53.46%
6M Performance:
-67.43%
1Y Performance:
-84.39%
1-Day Range:
Value
$3.69
$3.74
1-Week Range:
Value
$3.70
$6.24
52-Week Range:
Value
$3.70
$23.40

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
Name
Karyopharm Therapeutics Inc
Name
Phone
617-658-0600
Name
Address
85 WELLS AVENUE, NEWTON, MA
Name
Employee
0
Name
Twitter
@Karyopharm
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
KPTI's Discussions on Twitter

Compare KPTI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KPTI
Karyopharm Therapeutics Inc
3.71 36.61M 140.46M -146.34M -117.73M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
488.67 124.50B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
624.92 69.34B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.85 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
269.10 34.95B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
280.09 29.27B 3.81B -644.79M -669.77M -6.24

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-19-23 Initiated Piper Sandler Overweight
Nov-04-22 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-09-22 Upgrade JP Morgan Underweight → Neutral
Nov-19-21 Resumed Morgan Stanley Equal-Weight
Aug-06-21 Downgrade JP Morgan Overweight → Neutral
Aug-06-21 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-06-21 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-02-20 Initiated Morgan Stanley Overweight
Mar-04-20 Initiated Barclays Overweight
Jan-17-20 Downgrade Wedbush Outperform → Neutral
Jul-23-19 Upgrade JP Morgan Neutral → Overweight
Jul-05-19 Reiterated H.C. Wainwright Buy
Jul-05-19 Reiterated Robert W. Baird Outperform
Mar-01-19 Downgrade JP Morgan Overweight → Neutral
Feb-28-19 Reiterated BofA/Merrill Underperform
Feb-27-19 Downgrade BofA/Merrill Neutral → Underperform
Jan-03-19 Upgrade BofA/Merrill Underperform → Neutral
Dec-03-18 Initiated B. Riley FBR Buy
Nov-09-18 Upgrade Wedbush Neutral → Outperform
May-24-18 Downgrade Wedbush Outperform → Neutral
Apr-02-18 Resumed Leerink Partners Outperform
Nov-15-17 Resumed H.C. Wainwright Buy
Sep-15-17 Initiated RBC Capital Mkts Outperform
Sep-08-16 Reiterated H.C. Wainwright Buy
Aug-30-16 Upgrade Jefferies Hold → Buy
Aug-18-16 Initiated H.C. Wainwright Buy
Jun-28-16 Initiated Robert W. Baird Outperform
View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

pulisher
Mar 19, 2025

Piper Sandler cuts Karyopharm stock target to $15 from $75 - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Piper Sandler cuts Karyopharm stock target to $15 from $75 By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 11, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics SVP sells $17,567 in shares By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm Therapeutics Executives Sell Shares - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock - Investing.com

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics SVP sells $17,567 in shares - Investing.com India

Mar 06, 2025
pulisher
Mar 04, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $54.00 at Robert W. Baird - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizentribune

Mar 03, 2025
pulisher
Mar 03, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC)Bronstein, Gewirtz & Grossman, LLCClass Action Reminder - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM

Mar 03, 2025
pulisher
Mar 03, 2025

KPTI Stock Touches 52-Week Low at $7.58 Amid Market Challenges - Investing.com

Mar 03, 2025
pulisher
Mar 02, 2025

Karyopharm Therapeutics (KPTI) Projected to Post Earnings on Thursday - MarketBeat

Mar 02, 2025
pulisher
Mar 01, 2025

International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month - GlobeNewswire Inc.

Mar 01, 2025
pulisher
Mar 01, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $56.00 - Defense World

Mar 01, 2025
pulisher
Mar 01, 2025

HC Wainwright Forecasts Strong Price Appreciation for Karyopharm Therapeutics (NASDAQ:KPTI) Stock - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 93.1% in February - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 9%What's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Sees Large Volume Increase After Analyst Upgrade - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

HC Wainwright Issues Optimistic Estimate for KPTI Earnings - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

FY2025 Earnings Estimate for KPTI Issued By Leerink Partnrs - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 25, 2025

Research Analysts Issue Forecasts for KPTI Q1 Earnings - MarketBeat

Feb 25, 2025
pulisher
Feb 25, 2025

Royal Bank of Canada Reaffirms Outperform Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Feb 25, 2025
pulisher
Feb 25, 2025

Karyopharm announces 1-for-15 reverse stock split - MSN

Feb 25, 2025
pulisher
Feb 25, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia

Feb 25, 2025
pulisher
Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Announces 1-for-15 Reverse Stock Split - Citizentribune

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

Leerink Partnrs Has Pessimistic View of KPTI FY2025 Earnings - Defense World

Feb 24, 2025
pulisher
Feb 24, 2025

Research Analysts Offer Predictions for KPTI Q1 Earnings - Defense World

Feb 24, 2025
pulisher
Feb 23, 2025

What is Leerink Partnrs’ Estimate for KPTI Q1 Earnings? - The AM Reporter

Feb 23, 2025
pulisher
Feb 23, 2025

Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World

Feb 23, 2025
pulisher
Feb 22, 2025

Karyopharm’s 2024 Earnings and Clinical Progress - TipRanks

Feb 22, 2025
pulisher
Feb 21, 2025

HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Feb 21, 2025
pulisher
Feb 21, 2025

Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN

Feb 21, 2025
pulisher
Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm’s Earnings Call: Growth Amid Financial Challenges - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target - Investing.com India

Feb 20, 2025

Karyopharm Therapeutics Inc Stock (KPTI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.28
price down icon 1.54%
$31.31
price down icon 0.26%
$75.04
price down icon 2.96%
$19.23
price down icon 0.70%
$91.23
price up icon 0.15%
biotechnology ONC
$281.22
price up icon 5.24%
Cap:     |  Volume (24h):